Accessibility Menu
 
Telix Pharmaceuticals logo

Telix Pharmaceuticals

(ASX) TLX

Current Price$13.32
Market Cap$4.80B
Since IPO (2017)+1,736%
5 Year+233%
1 Year-47%
1 Month-7%

Telix Pharmaceuticals Financials at a Glance

Market Cap

$4.80B

Revenue (TTM)

$2.01B

Net Income (TTM)

$39.06M

EPS (TTM)

$-0.03

P/E Ratio

-435.08

Dividend

$0.00

Beta (Volatility)

-0.09 (Low)

Price

$13.32

Volume

4,877,150

Open

$14.08

Previous Close

$13.32

Daily Range

$13.23 - $14.19

52-Week Range

$8.26 - $27.40

TLX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telix Pharmaceuticals

Industry

Biotechnology

Employees

234

CEO

Christian P. Behrenbruch, PhD, EMBA

Headquarters

North Melbourne, VIC 3051, AU

TLX Financials

Key Financial Metrics (TTM)

Gross Margin

51%

Operating Margin

2%

Net Income Margin

-1%

Return on Equity

-2%

Return on Capital

2%

Return on Assets

-1%

Earnings Yield

-0.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.80B

Shares Outstanding

339.38M

Volume

4.88M

Avg. Volume

2.70M

Financials (TTM)

Gross Profit

$662.07M

Operating Income

$27.55M

EBITDA

$61.33M

Operating Cash Flow

$26.82M

Capital Expenditure

$58.80M

Free Cash Flow

$85.62M

Cash & ST Invst.

$212.74M

Total Debt

$785.24M

Telix Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$630.94M

+124.0%

Gross Profit

$332.97M

+48.7%

Gross Margin

52.77%

N/A

Market Cap

$4.80B

N/A

Market Cap/Employee

$11.56M

N/A

Employees

415

N/A

Net Income

$7.38M

-137.8%

EBITDA

$28.18M

+44.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$572.50M

-644.2%

Accounts Receivable

$207.50M

+220.3%

Inventory

$55.60M

+221.2%

Long Term Debt

$757.26M

+4666.9%

Short Term Debt

$27.98M

+1198.9%

Return on Assets

-0.61%

N/A

Return on Invested Capital

1.81%

N/A

Free Cash Flow

$94.51M

-3427.7%

Operating Cash Flow

$54.37M

-611.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANN.AXAnsell Limited
$26.25+0.61%
EBO.AXEBOS Group Limited
$16.56-0.54%
MSB.AXMesoblast Limited
$2.12+2.42%
NEU.AXNeuren Pharmaceuticals Limited
$13.67+4.83%

Trending Stocks

Symbol / CompanyPricePrice Chg
FFord Motor Company
$14.93+0.09%
AALAmerican Airlines Group
$13.85+0.02%
INFQInfleqtion
$16.35+0.11%
TET1 Energy Inc.
$8.08-0.07%

Questions About TLX

What is the current price of Telix Pharmaceuticals?

Telix Pharmaceuticals is trading at A$13.32 per share.

What is the 52-week range for Telix Pharmaceuticals?

Over the past 52 weeks, Telix Pharmaceuticals has traded between A$8.26 and A$27.40.

How much debt does Telix Pharmaceuticals have?

As of the most recent reporting period, Telix Pharmaceuticals reported total debt of $22.14M.

How much cash does Telix Pharmaceuticals have on hand?

Telix Pharmaceuticals reported $118.84M in cash and cash equivalents in its most recent financial results.

What is Telix Pharmaceuticals’s dividend yield?

Telix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.